Order Article Reprints

Ortiz-Pérez E, Moreno-Rodríguez A, Delgado-Maldonado T, Ortega-Balleza JL, González-González A, Paz-González AD, Vázquez K, Avalos-Navarro G, Giovannuzzi S, Supuran CT, et al. Repositioning FDA-Approved Sulfonamide-Based Drugs as Potential Carbonic Anhydrase Inhibitors in Trypanosoma cruzi: Virtual Screening and In Vitro Studies. Pharmaceuticals. 2025; 18(5):669. https://doi.org/10.3390/ph18050669

Ortiz-Pérez, Eyra, Adriana Moreno-Rodríguez, Timoteo Delgado-Maldonado, Jessica L. Ortega-Balleza, Alonzo González-González, Alma D. Paz-González, Karina Vázquez, Guadalupe Avalos-Navarro, Simone Giovannuzzi, Claudiu T. Supuran, and et al. 2025. "Repositioning FDA-Approved Sulfonamide-Based Drugs as Potential Carbonic Anhydrase Inhibitors in Trypanosoma cruzi: Virtual Screening and In Vitro Studies" Pharmaceuticals 18, no. 5: 669. https://doi.org/10.3390/ph18050669

Ortiz-Pérez, E., Moreno-Rodríguez, A., Delgado-Maldonado, T., Ortega-Balleza, J. L., González-González, A., Paz-González, A. D., Vázquez, K., Avalos-Navarro, G., Giovannuzzi, S., Supuran, C. T., & Rivera, G. (2025). Repositioning FDA-Approved Sulfonamide-Based Drugs as Potential Carbonic Anhydrase Inhibitors in Trypanosoma cruzi: Virtual Screening and In Vitro Studies. Pharmaceuticals, 18(5), 669. https://doi.org/10.3390/ph18050669